

PI3 Kinase p85/p55(Ab-467/199) Antibody

Catalog No: #21508

Package Size: #21508-1 50ul #21508-2 100ul

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com

Description


Product Name	PI3 Kinase p85/p55(Ab-467/199) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Applications	IHC
Species Reactivity	Hu Ms Rt
Specificity	The antibody detects endogenous level of total PI3 Kinase p85/p55 protein.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around aa.465~469(L-Y-E-E-Y) derived from Human PI3 Kinase p85/p55.
Conjugates	Unconjugated
Target Name	PI3 Kinase p85/p55
Other Names	p85, AGM7, p85-ALPHA, p55, p55-GAMMA
Accession No.	Swiss-Prot:P27986Gene ID:5295
SDS-PAGE MW	55, 85kd
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

Application Details

Predicted MW: 55, 85kd

Immunohistochemistry: 1:50~1:100

Images



Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using PI3K P85 a/g/b(Ab-467/199/464) Antibody #21508(left) or the same antibody preincubated with blocking peptide(right).

Background

PI3K binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues.

Stoyanov, B. et al. (1995) Science 269, 690-3.

Simpson, L. and Parsons, R. (2001) Exp Cell Res 264, 29-41.

Neri, L.M. et al. (2002) Biochim Biophys Acta 1584, 73-80.

Published Papers

el at., Fatty Acid Synthase Regulates Proliferation and Migration of Colorectal Cancer Cells via HER2-PI3K/Akt Signaling Pathway. In Nutr Cancer on 2012 Aug by Nan Li, Xiaodong Bu, et al.. PMID:22860766, , (2012)

[PMID:22860766](#)

el at., Loss of Fatty Acid Synthase Inhibits the "HER2-PI3K/Akt Axis" Activity and Malignant Phenotype of Caco-2 Cells. In Lipids Health Dis on 2013 Jun 1 by Nan Li, Heng Lu, et al.. PMID:23725225, , (2013)

[PMID:23725225](#)

el at., The ζ -ERK1/2- ζ -PI3K/Akt ζ -ASN Axis Regulated Malignant Phenotype of Colorectal Cancer Cells. In Lipids on 2012 Apr by Nan Li, Xiaodong Bu, et al.. PMID:22218925, , (2012)

[PMID:22218925](#)

el at., Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811. In Am J Transl Res. On 2016 Sep 15 by SH Li, WC Dong et al.. PMID:27725861, , (2016)

[PMID:27725861](#)

el at., CPU-12, a novel synthesized oxazolo [5, 4-d] pyrimidine derivative, showed superior anti-angiogenic activity. In J Pharmacol Sci on 2015 Sep by Jiping Liu, Ya-Hui Deng et al.. PMID: 26154846, , (2015)

[PMID:26154846](#)

el at., An alternatively spliced variant of CXCR3 mediates the metastasis of CD133+ liver cancer cells induced by CXCL9. In Oncotarget on 2016 Mar 22 by Qiang Ding, Yujia Xia et al.. PMID:26883105, , (2016)

[PMID:26883105](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.